KALA BIO, Inc. (NASDAQ: KALA) has implemented a 1-for-50 reverse stock split of its common stock, effective at 4:05 p.m. on May 8, 2026. The split-adjusted shares will begin trading on the Nasdaq Capital Market at the open on May 11, 2026. This corporate action reduces the company's outstanding common shares from approximately 929.5 million to 18.6 million. Cash payments will be issued in lieu of fractional shares, and proportional adjustments will be made to outstanding equity awards, warrants, and other convertible securities.
The reverse stock split is a strategic move to increase the per-share trading price of KALA BIO's common stock, likely to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. For companies trading at very low share prices, reverse splits are often used to avoid delisting and maintain investor confidence. However, such actions can also signal financial distress and may lead to reduced liquidity in the short term.
KALA BIO is a clinical-stage biopharmaceutical company that is building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The company's dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business. This AI platform is designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.
Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows.
For more information about the company, please visit Researgency.ai. The full press release is available at https://ibn.fm/yUznR.
